Skip to main navigation Skip to search Skip to main content

Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures

  • Shankha Satpathy
  • , Natalie M. Clark
  • , Yi Ju Chen
  • , Noshad Hosseini
  • , Ya Hsuan Chang
  • , Yi Hsiao
  • , Jonathan T. Lei
  • , Francesca Petralia
  • , Jin Shing Chen
  • , Yifat Geffen
  • , David I. Heiman
  • , Indranil Paul
  • , Hanbyul Cho
  • , Michelle Hollenberg
  • , Giacomo B. Marino
  • , Kuen Tyng Lin
  • , Rahul Mannan
  • , C. Jackson White
  • , Joe Allen
  • , Shayan C. Avanessian
  • M. Harry Kane, Ashley Wolfe, Miloni Kinarivala, Wenke Liu, Shankara Anand, Mong Wei Lin, Moe Haines, Erik J. Bergstrom, Grant Hussey, Ginny Xiaohe Li, Deepak C. Mani, Hao Fang, Eric J. Jaehnig, Hasmik Keshishian, Brecca Miller, Kang Yi Su, Yi Jing Hsiao, Hsao Hsun Hsu, Min Shu Hsieh, Kuo Hsuan Hsu, Alexi Monovoukas, Simone Gohsman, John R. Thorup, Yamei Deng, Yo Akiyama, Eden Deng, Eric Sheng-Wen Chen, Azra Krek, Rodrigo Espinoza, Weiping Ma, Daniel Charytonowicz, Robert Sebra, Jyun Hong Lin, Yan Si Chen, Yin Chen Hsu, Ze Shiang Lin, Kun Chieh Chen, Chang Wei Yeh, Yu Tai Wang, Alexander J. Lazar, Mehdi Mesri, Eunkyung An, Xu Zhang, Karl R. Clauser, David Fenyö, Arul M. Chinnaiyan, Bing Zhang, Li Ding, Kelly Ruggles, Chelsea Newton, Hui Zhang, Pei Wang, Galen Hostetter, Gilbert S. Omenn, Chandan Kumar-Sinha, Mathangi Thiagarajan, Ramaswamy Govindan, Paul Paik, Abhijit Parolia, Qing K. Li, Avi Ma'ayan, Gad A. Getz, Saravana M. Dhanasekaran, Ana I. Robles, Gee Chen Chang, Pan Chyr Yang, Sung Liang Yu, Hsuan Yu Chen, Alexey I. Nesvizhskii, Steven A. Carr, D. R. Mani, Marcin P. Cieslik, Yu Ju Chen, Michael A. Gillette, Chao Wen Lu, Cheng Hsiang Chu, Chi Ya Shen, Chia Li Han, Chien Chia Lin, Chien Yu Lin, Ching Wen Chen, Chung Hsien Lin, Hsiang En Hsu, Hsing Jui Tsai, Jia Jun Wu, Jing Wei Lin, Juani Waniwan, Ki Hok Liao, Pei Hsing Chen, Pei Rong Huang, Sin Ming Huang, Tai Ching Lin, Wan Chun Lai, Wei Tzu Chiu, Xu Heng Chiang, Ya Ling Chang, Yan Ming Chen, Yi Ling Chen, Yi Wen Wang, Yi Wei Lin, Yu Cheng Chang, Yu Ting Huang, Yuju Lien, Zhe Rong Zheng, Abdul Samad Hashimi, Adrij Mohan, Akhilesh Pandey, Alexander Pilozzi, Alex Webster, Amanda G. Paulovich, Aniket Dagar, Andrew K. Godwin, Barbara Pruetz, Bart O. Williams, Brian J. Druker, Daniel C. Rohrer, Daniel W. Chan, Danail Petrov, David Chesla, Diwakar Davaar, Elizabeth Duffy, George D. Wilson, Grace Zhao, Iga Kołodziejczak, Jan Lubinski, Jasmine Huang, Jason Hafron, Jeffrey W. Tyner, John Koomen, Kakhaber Zaalishvili, Karen A. Ketchum, Maciej Wiznerowicz, Marcin J. Domagalski, Meenakshi Anurag, Melissa Borucki, Nathan J. Edwards, Negin Vatanian, Pamela Grady, Paul D. Piehowski, Popovici Bogdan, Qin Li, Rafael Fonseca, Rashna Madan, Ratna R. Thangudu, Reese Crispen, Ronald Matteotti, Ross Bremner, Sandra Cerda, Sandra L. Cottingham, Shirley Tsang, Shuang Cai, Tao Liu, Thomas Bauer, William W. Maggio, Xiaojun Jing, Yuping Zhang, Yvonne Shutack, Zoran Andric
  • Broad Institute
  • Academia Sinica Taiwan HQ
  • University of Michigan, Ann Arbor
  • National Health Research Institutes Taiwan
  • Baylor College of Medicine
  • Icahn School of Medicine at Mount Sinai
  • National Taiwan University
  • Massachusetts General Hospital
  • New York University
  • Veterans General Hospital-Taichung Taiwan
  • Chung Shan Medical University
  • National Applied Research Laboratories Taiwan
  • University of Texas MD Anderson Cancer Center
  • National Institutes of Health
  • Washington University St. Louis
  • Van Andel Institute
  • Johns Hopkins University
  • Leidos Inc
  • Memorial Sloan-Kettering Cancer Center
  • Cornell University
  • National Chung Hsing University

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Lung adenocarcinomas (LUAD) are a pressing global health problem with enduring lethality and rapidly shifting epidemiology. Proteogenomic studies integrating proteomics and post-translational modifications with genomics can identify clinical strata and oncogenic mechanisms, but have been underpowered to examine effects of ethnicity, smoking and environmental exposures, or sex on this heterogeneous disease. This comprehensive proteogenomic analysis of LUAD tumors and matched normal adjacent tissues from 406 patients across diverse geographic and demographic backgrounds explores the impact of understudied driver mutations, prognostic role of chromosomal instability, patterns of immune signaling, differential and sex-specific effects of endogenous mutagens and environmental carcinogens, and pathobiology of early-stage tumors with “late-like” characteristics. Candidate protein biomarkers are proposed for unstable tumors with highly fragmented genomes and for carcinogen exposures, and a LUAD subtype-specific atlas of therapeutic vulnerabilities is presented. These observations and the associated data resource advance the objective of precision management strategies for this devastating disease.

Original languageEnglish
Pages (from-to)1731-1757.e17
JournalCancer Cell
Volume43
Issue number9
DOIs
StatePublished - 8 Sep 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • CPTAC
  • ICPC
  • PTMs
  • biomarkers
  • genomics
  • lung adenocarcinoma
  • mass spectrometry
  • never-smokers
  • proteogenomics
  • smokers

Fingerprint

Dive into the research topics of 'Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures'. Together they form a unique fingerprint.

Cite this